07/06/2017
Additional Testing for GammaTile™ Planned for Completion by Year-End 2017
RICHLAND, Wash., July 6, ...
06/20/2017
Study Demonstrates 100% Freedom from Local Progression Rate & 0% Rate of Radionecrosis
RICHLAND, Wash., June ...
05/03/2017
At Median 5.5 Years Post-Treatment, Return to Baseline is Sustained
RICHLAND, Wash., May 3, 2017 /PRNewswire/ -- ...
04/18/2017
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical ...
03/09/2017
Settlement Fully Funded by D&O Insurance
RICHLAND, Wash., March 9, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE ...
02/08/2017
Management Continues to Expect Stronger Second Half of Fiscal 2017
RICHLAND, Wash., Feb. 8, ...
12/21/2016
RICHLAND, Wash., Dec. 21, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and ...
11/30/2016
RICHLAND, Wash., Nov. 30, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and ...
11/29/2016
Preliminary Results Suggest Surgery Plus GammaTile™ Extends Median Time to Surgical Site Recurrence
RICHLAND, ...
11/08/2016
Management Continues to Expect Stronger Second Half of Fiscal 2017
RICHLAND, Wash., Nov. 8, 2016 /PRNewswire/ ...
10/20/2016
RICHLAND, Wash., Oct. 20, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR) (the "Company"), a medical technology
09/28/2016
Expanded Information and Resources for Brachytherapy and its Efficacy with Multiple Cancers
RICHLAND, Wash., Sept.
Media & Public Relations Contact
If you have questions or need help, please contact Sharon Schultz:
Sharon Schultz
Public and Media Relations